Navigation Links
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Date:4/29/2009

is related to edema and the growth of abnormal new blood vessels that are mediated by vascular endothelial growth factor (VEGF), we are hopeful that VEGF Trap-Eye may help address this significant unmet medical need."

About CRVO

Over 100,000 people in the United States are estimated to suffer from CRVO. CRVO is caused by obstruction of the central retinal vein that leads to a back up of blood and fluid in the retina, resulting in retinal injury and loss of vision. The retina can also become "ischemic" (starved for oxygen), resulting in the growth of new abnormal blood vessels that can cause further vision loss and more serious complications. Release of VEGF contributes to increased vascular permeability in the eye and abnormal new vessel growth. It is believed that anti-VEGF treatment may help decrease vascular permeability and edema and prevent the growth of abnormal new blood vessels in the retina in patients with CRVO.

About the Phase 3 CRVO Program

In the Phase 3 CRVO program for VEGF Trap-Eye, Regeneron and Bayer HealthCare will conduct two identical multinational clinical studies: COPERNICUS (COntrolled Phase 3 Evaluation of Repeated iNtravitreal administration of VEGF Trap-Eye In Central retinal vein occlusion: Utility and Safety) will be led by Regeneron and GALILEO (General Assessment Limiting InfiLtration of Exudates in central retinal vein Occlusion with VEGF Trap-Eye) will be led by Bayer HealthCare. Enrollment will be initiated later in 2009.

Patients in both studies will receive 6 monthly intravitreal injections of either VEGF Trap-Eye at a dose of 2 milligrams (mg) or sham control injections. The primary endpoint of both studies is improvement in visual acuity versus baseline after 6 mon
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; Bayer HealthCare AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
2. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
3. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
4. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
5. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
8. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
9. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
10. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
11. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- It can happen ... television, dresser or computer monitor and gets critically injured ... of a young child should look around their homes and ... a child. Imagining it is better than it becoming a ... Emergency Physicians, said in a college news release. Between ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Visitors to ... contributed over $8,500 to ensure its protection. Bob Kiesendahl, ... a check to the Delaware Highlands Conservancy for donations ... The small $2-per-stay donations add up fast, as visitors ... the Upper Delaware River Region. , The Kiesendahl family ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
(Date:7/30/2014)... ... ... ... , UCLA ... For the study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. ...
Breaking Medicine News(10 mins):Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... A University of Melbourne study has revealed that certain ... link between mammographic breast density and breast cancer. ... Health says women vary greatly in their underlying risk ... possible new pathways into the development of breast cancer." ...
... Del.Feb. 16, 2010 Cancer , the peer-reviewed international ... a study conducted by HealthCore, Inc. in its ... treatment between commercially insured African-American and white women. ... of previous studies conducted in populations using ...
... team of researchers has found that adding a humanized monoclonal ... new or enlarged brain lesions in patients with relapsing multiple ... and in the March edition of the Lancet Neurology ... which the body,s immune system attacks the fatty substance that ...
... Celebrity ... will be awarded $5,000 for best eye care tips., , ... Atlanta, GA (Vocus) February 16, 2010 -- Just as people ... the AIR OPTIX AQUA brand team is partnering with Carmindy, makeup artist on TLC’s hit ...
... with the worst cases report the fewest nightmares, study finds ... that accompany severe sleep apnea may be counterbalanced by this ... , "We found that people with significant sleep apnea have ... fewer nightmares," said Dr. Jim Pagel, lead author of a ...
... ... the use of social tools. , ... Minneapolis, MN (PRWEB) February 16, 2010 -- BusinessCard2 ™, a ... of the Social Business Innovation Awards. The competition was established to recognize great ...
Cached Medicine News:Health News:Study reveals genetic link between mammographic density and breast cancer 2Health News:Cancer publishes study confirming disparity in breast cancer treatment 2Health News:Promising therapy for relapsing multibple sclerosis 2Health News:Promising therapy for relapsing multibple sclerosis 3Health News:CIBA VISION Partners with TLC's Carmindy to Educate Consumers About Healthy Eye Habits 2Health News:CIBA VISION Partners with TLC's Carmindy to Educate Consumers About Healthy Eye Habits 3Health News:CIBA VISION Partners with TLC's Carmindy to Educate Consumers About Healthy Eye Habits 4Health News:Severe Sleep Apnea Has Silver Lining 2Health News:Severe Sleep Apnea Has Silver Lining 3Health News:BusinessCard2 Wins Social Business Innovation Award 2Health News:BusinessCard2 Wins Social Business Innovation Award 3
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: